• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Kala Pharmaceuticals: EYSUVIS now covered on UnitedHealthcare Commercial, Cigna Medicare

Article

Effective this month, the coverage applies to approximately 70% of all United Healthcare commercial lives.

EYSUVIS now covered on UnitedHealthcare Commercial, Cigna Medicare


United Healthcare has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on the company’s commercial formularies, Kala Pharmaceuticals announced on Tuesday.

Effective this month, the coverage applies to approximately 70% of all commercial lives — 118 million individuals, according to a news release.

Further, Cigna Medicare has also added EYSUVIS as a preferred brand, effective February 2022, Kala stated. With this latest addition, EYSUVIS has coverage via Medicare for select plans with Express Scripts, Prime Therapeutics, and Cigna — totaling 15% of all Medicare lives.

EYSUVIS became commercially available in January 2021. It is the first and only FDA-approved medicine for short-term treatment of the signs and symptoms of dry eye.

Related Videos
Mila Ioussifova, OD, FAAO
Tracy Doll, OD, FAAO
© 2024 MJH Life Sciences

All rights reserved.